The activation visit is done. The pharmacy is qualified. The PI has signed everything. And then the question nobody wants to answer out loud: where is the investigational product? Not the shipment tracking number, not the estimated delivery window from the central depot, the actual, temperature-verified, chain-of-custody-confirmed kit for patient one. At too many sites, the honest answer is that no one person holds that thread from manufacture to site freezer. That gap, invisible on a Gantt chart and rarely named in a study startup meeting, is where enrollment timelines go to die.
Decentralized supply management, getting IP to patients and sites through models that bypass the traditional single-depot, CRA-verified handoff, now touches 87.3% of surveyed sites that hosted at least one trial with decentralized elements, according to 2024 data. That number should prompt a hard operational question, and it rarely does: if the supply model is decentralized, who owns the oversight?
The Cold Chain Gap Nobody Budgets For
The pharmaceutical industry loses an estimated $35 billion annually to cold chain failures, with individual shipment losses sometimes exceeding $500,000 per load. Those are industry-level figures. Translate them to the site level and they look different but no less painful: a temperature excursion on a frozen biologic kit means a replacement request, a pharmacy re-qualification, a delay in dosing the first enrolled patient, and a deviation log entry that will sit in front of a monitor on the next visit. The site coordinator files the deviation. The sponsor counts the days. The enrollment projection built into the study budget does not account for any of it.
Traditional centralized supply models put the CRA in the loop at the point of shipment confirmation and site receipt. The monitor verified chain-of-custody documentation at the site visit, reconciled pharmacy logs against the IRT, and flagged discrepancies before they became protocol deviations. That sequence assumed the depot was one place, the site was one place, and the path between them was linear. Direct-to-patient and direct-to-local-pharmacy models break every one of those assumptions simultaneously.
Sites I work with have received IP at a local specialty pharmacy that had no prior relationship with the sponsor’s central lab, no established temperature monitoring protocol for that specific product, and no trained staff for IRT reconciliation, all within a study that had a 45-day activation target. The sponsor’s clinical supply team knew the kit shipped. The site’s coordinator found out when the pharmacy called asking what to do with it.
That is a coordination failure, and it costs time the enrollment ramp cannot recover.
What a DSM Vendor Actually Touches at the Site Level
A decentralized supply management vendor, when integrated properly, handles depot selection, regional distribution, temperature monitoring, last-mile logistics, and IRT reconciliation across a fragmented delivery network. The operative phrase is “when integrated properly.” The FDA’s 2024 guidance on conducting clinical trials with decentralized elements explicitly addresses supply logistics: it requires that sponsors ensure drug accountability, temperature control, and chain-of-custody documentation regardless of where trial-related activities occur. The guidance places accountability on the sponsor. The operational weight lands on whichever vendor or site is holding the product at any given moment.
That accountability chain only works if the site coordinator has a single, clear escalation path when something goes wrong with a shipment. In practice, sites often field calls from three separate vendors, the IRT platform, the logistics carrier, and the central lab, none of whom have a shared view of the same shipment. Every minute a coordinator spends triangulating between vendor portals is a minute not spent on patient contact, screen visits, or the deviation narrative due by end of week.
The operational cost here is not just delay. Screen failure rates climb when enrollment windows compress. A site that expected to dose its first patient in week six and instead doses in week nine has already lost three weeks of the enrollment curve. Across a network of fifteen sites, that compression can push a study past its interim analysis readiness date, which changes the data lock timeline, which affects the sponsor’s regulatory submission plan. The DSM handoff is not an administrative detail; it is a load-bearing beam in the enrollment architecture.
What Operators Need to Fix Before the Next Activation
The site-side fix is procedural and it needs to happen before the SIV, not during it. Every site taking on a study with decentralized supply elements should have a named pharmacy or storage contact, a temperature excursion response SOP aligned with ICH E6(R3) requirements for investigational product accountability, and a written escalation path to the sponsor’s clinical supply team that does not route through the CRA as the sole point of contact. If the study startup package does not include that escalation contact, ask for it before you sign the budget. Once the site is activated and the first kit ships, the window to establish those relationships has already closed.
Sponsor-side clinical operations teams need to run a supply integration audit as part of their DSM vendor selection process, not after contract execution. That audit should confirm whether the vendor’s IRT reconciliation data feeds directly into the CTMS or requires manual entry at the site level, and whether the vendor has an established process for local pharmacy onboarding that does not rely on the site coordinator to do the training. Across the trials in our network, the sites that hit 45-day activation targets in studies with decentralized supply elements had one thing in common: the supply vendor had a documented site onboarding checklist that was shared before the qualification visit, not handed over at the SIV. That two-week difference in information timing is the difference between a site that is ready and a site that is reactive.
The DSM vendor selection decision gets made at the sponsor level, often before sites are even identified. But the operational consequences of a poor selection land entirely at the site, in the pharmacy, in the deviation log, and in the enrollment report that gets read on the next sponsor oversight call. Site directors who treat supply chain as someone else’s problem until the first kit arrives are setting up their coordinators to absorb a failure that was baked in months earlier.
The next time a sponsor hands your team a study startup package for a decentralized or hybrid supply model, the first question worth asking is not “when does the first kit ship?” It is “who do we call at 4 PM on a Friday when the temperature logger on that kit reads out of range, and how fast can they authorize a replacement?”
References
- ARDEM, “Cost of Cold Chain Failures in Pharmaceutical Supply”
- Federal Register, “Conducting Clinical Trials With Decentralized Elements: Guidance for Industry, Investigators, and Other Stakeholders” (September 2024)
- Fortune Business Insights, Decentralized Clinical Trials Market, 2024 Data
- Clinical Trials Arena, “The operational backbone of clinical supply: Why DSMs matter more than ever”
